Diaceutics PLC (DXRX) - Total Assets
Based on the latest financial reports, Diaceutics PLC (DXRX) holds total assets worth GBX44.42 Million GBX (≈ $5.40K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Diaceutics PLC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Diaceutics PLC - Total Assets Trend (2015–2024)
This chart illustrates how Diaceutics PLC's total assets have evolved over time, based on quarterly financial data. Explore Diaceutics PLC (DXRX) long-term investment share to see how much of total assets are deployed in long-term investments.
Diaceutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Diaceutics PLC's total assets of GBX44.42 Million consist of 60.7% current assets and 39.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 26.2% |
| Accounts Receivable | GBX14.96 Million | 30.8% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX15.41 Million | 31.7% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Diaceutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Diaceutics PLC.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Diaceutics PLC's current assets represent 60.7% of total assets in 2024, a decrease from 98.7% in 2015.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2024, up from 9.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 1.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 31.7% of total assets.
Diaceutics PLC Competitors by Total Assets
Key competitors of Diaceutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Heren Health Co Ltd
SHE:300550
|
China | CN¥1.42 Billion |
|
Painchek Ltd
AU:PCK
|
Australia | AU$2.15 Million |
|
Careteq Ltd
AU:CTQ
|
Australia | AU$4.44 Million |
|
Newtopia Inc
V:NEWU
|
Canada | CA$664.83K |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$92.19 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
Diaceutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.96 | 4.85 | 23.05 |
| Quick Ratio | 3.96 | 4.85 | 23.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX18.28 Million | GBX21.62 Million | GBX34.27 Million |
Diaceutics PLC - Advanced Valuation Insights
This section examines the relationship between Diaceutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | GBX48.62 Million |
| Market Capitalization | $1.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Diaceutics PLC's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Diaceutics PLC's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Diaceutics PLC (2015–2024)
The table below shows the annual total assets of Diaceutics PLC from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX48.62 Million ≈ $5.92K |
+4.91% |
| 2023-12-31 | GBX46.34 Million ≈ $5.64K |
-3.96% |
| 2022-12-31 | GBX48.26 Million ≈ $5.87K |
+7.20% |
| 2021-12-31 | GBX45.01 Million ≈ $5.48K |
+3.43% |
| 2020-12-31 | GBX43.52 Million ≈ $5.30K |
+94.53% |
| 2019-12-31 | GBX22.37 Million ≈ $2.72K |
+186.43% |
| 2018-12-31 | GBX7.81 Million ≈ $950.30 |
+42.23% |
| 2017-12-31 | GBX5.49 Million ≈ $668.16 |
+59.61% |
| 2016-12-31 | GBX3.44 Million ≈ $418.61 |
+156.49% |
| 2015-12-31 | GBX1.34 Million ≈ $163.21 |
-- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which d… Read more